You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The single-cell RNA-sequencing analysis found that undifferentiated ependymomas are more likely to be linked to a poorer prognosis.
While a subset of metastatic castration-resistant tumors was marked by enhanced methylation, the analysis also pointed to recurrently hypomethylated regions.
The analysis suggested survival and other benefits for breast cancer patients with BRCA1/2 mutations who were aware of their germline risk before diagnosis.
Some genes were more frequently mutated in prostate cancers from Black men, but the researchers said that social inequities also lead to poorer health outcomes.
Analyzing both circulating tumor DNA and circulating tumor cells, investigators could classify patients into groups with significantly higher and lower recurrence risk.
Transcriptomic and multi-omic data spanning more than 10,000 samples helped map "immunogenomic" interactions that may inform treatment outcomes and targets.
Three research teams profiled proteomic, genomic, and other features in lung adenocarcinomas in Asia and other parts of the world, including cases in never-smokers.
Belgium-based OncoDNA will purchase France's IntegraGen as part of its plans to provide a solution that combines oncology laboratory testing and bioinformatics software.
M2Gen has seen its research database grow substantially, but now the firm must make the data useful across its clinical, pharma, and MDx partners.
Researchers concluded that there has been significant expansion of coverage for ctDNA assays over the past four years, but policies remain very heterogeneous and often limited.
Researchers saw similar cell hierarchies and progenitor cell clusters when comparing single-cell RNA sequencing data for cells from glioblastoma tumors and developing brains.
The companies will work together to bring Guardant360 through regulatory approval and commercialize it as a CDx for Janssen's amivantamab.
Thermo Fisher has also applied to the Japanese Ministry of Health, Labor, and Welfare to expand the use of the Oncomine Dx Target test in Japan.
The initial investment is led by Debiopharm, which will collaborate with the Israeli startup to accelerate discovery of biomarkers for oncology drug response.
Abcam will develop custom protein-based reagents for targets identified by researchers funded by Cancer Research UK.
A Myriad Genetics-funded team found that an 86-SNV polygenic score could modify breast cancer risk in women with pathogenic mutations in cancer risk genes.
Investors in the company, formerly known as Vermillion, have agreed to purchase $11 million in unregistered common stock at a price of $3.50 per share.
The company recently presented results from its Aurora assay for multi-cancer screening and plans to launch a $100 test for the US and Chinese markets.
OncoCyte will cease further development of a liquid biopsy test that used an immune system interrogation approach to clarify whether patients’ lung nodules are benign.
In a separate study, researchers studying the use of Oncotype DX in African-American men found it to be predictive of disease outcomes regardless of race.
A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.
US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.
According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.
In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.